Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

Betsy Goodfellow | December 6, 2023 | News story | Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity 

Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of migraine prevention treatment, Ajovy (fremanezumab) in the reduction of migraine attacks in patients with migraine and co-morbid obesity.

The analysis of the HALO-LTS and FOCUS phase 3 studies compared the safety and efficacy of the drug in obese migraine patients to normal weight migraine patients for six months. It was demonstrated that the efficacy of Ajovy remained consistent between BMI-high and BMI-normal patients.

Ajovy is a humanised monoclonal antibody (mAB) which selectively targets the calcitonin gene-related peptide (CGRP) approved for the prevention of migraine in adults who have at least four migraine days per month.

Dr Pablo Irimia Sieria, lead study author and consultant neurologist of the Clinica Universidad de Navarra, Pamplona, Spain, commented: “This analysis is encouraging as it shows fremanezumab can reduce migraine attacks as effectively in obese patients as it does in patients of normal weight. Considering the higher burden of migraine in patients with co-morbid obesity, it is important for treatments to demonstrate efficacy and safety in migraine patients with this particular comorbidity.”

Betsy Goodfellow

Related Content

national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in …

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset …

weight-2036971_960_720

UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Latest content